Unknown

Dataset Information

0

Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.


ABSTRACT: The activation of the N-methyl D-aspartate receptor (NMDAR) is controlled by a glutamate-binding site and a distinct, independently regulated, co-agonist-binding site. In most brain regions, the NMDAR co-agonist is the astrocyte-derived gliotransmitter D-serine. We found that D-serine levels oscillate in mouse hippocampus as a function of wakefulness, in vitro and in vivo. This causes a full saturation of the NMDAR co-agonist site in the dark (active) phase that dissipates to sub-saturating levels during the light (sleep) phase, and influences learning performance throughout the day. We demonstrate that hippocampal astrocytes sense the wakefulness-dependent activity of septal cholinergic fibers through the ?7-nicotinic acetylcholine receptor (?7nAChR), whose activation drives D-serine release. We conclude that astrocytes tune the gating of synaptic NMDARs to the vigilance state and demonstrate that this is directly relevant to schizophrenia, a disorder characterized by NMDAR and cholinergic hypofunctions. Indeed, bypassing cholinergic activity with a clinically tested ?7nAChR agonist successfully enhances NMDAR activation. VIDEO ABSTRACT.

SUBMITTER: Papouin T 

PROVIDER: S-EPMC5484087 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.

Papouin Thomas T   Dunphy Jaclyn M JM   Tolman Michaela M   Dineley Kelly T KT   Haydon Philip G PG  

Neuron 20170504 4


The activation of the N-methyl D-aspartate receptor (NMDAR) is controlled by a glutamate-binding site and a distinct, independently regulated, co-agonist-binding site. In most brain regions, the NMDAR co-agonist is the astrocyte-derived gliotransmitter D-serine. We found that D-serine levels oscillate in mouse hippocampus as a function of wakefulness, in vitro and in vivo. This causes a full saturation of the NMDAR co-agonist site in the dark (active) phase that dissipates to sub-saturating leve  ...[more]

Similar Datasets

| S-EPMC5745065 | biostudies-literature
| S-EPMC3690137 | biostudies-literature
| S-EPMC8594917 | biostudies-literature
| S-EPMC3134790 | biostudies-literature
| S-EPMC7914286 | biostudies-literature
| S-EPMC5828580 | biostudies-literature
| S-EPMC4648333 | biostudies-literature
| S-EPMC2877140 | biostudies-literature
| S-EPMC7812756 | biostudies-literature
| S-EPMC7864875 | biostudies-literature